{'fraction_non_alphanumeric': 0.015483870967741935, 'fraction_numerical': 0.0, 'mean_word_length': 5.5210084033613445, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.

OBJECTIVE
While gynaecological cancer patients who participate in Phase I clinical trials are not routinely considered for elective surgery because of a short life expectancy, this should not be overlooked in carefully selected responding patients.


METHODS/RESULTS
We describe two cases of patients with different gynaecological cancers, who received treatment within separate phase I trials, and who then proceeded to surgical resection of their cancers, resulting in complete remission.


CONCLUSION
Surgery, when feasible, should be taken into consideration as a potential management option, even when patients are receiving treatment within a phase I trial.